
Opinion|Videos|August 20, 2024
Optimizing MOAs of JAK Inhibitors in a 36-Year-Old Male With a History of Atopic Dermatitis
Author(s)Jayme M. Heim, MSN, FNP-BC
Jayme Heim, MSN, FNP-BC, explores strategies for optimizing the mechanisms of action of topical JAK inhibitors in treating a 36-year-old male patient with a history of atopic dermatitis, highlighting the potential benefits and considerations of this therapeutic approach.
Advertisement
Episodes in this series

Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Next-Generation IL-4Rα Targeting and Potential Dermatologic Implications
2
Comparative Analysis Positions Zasocitinib Among Next-Generation TYK2 Inhibitors
3
Utilizing CYP2C9 Testing and JAK Inhibitors for Alopecia Areata
4
Timing, Severity, and Therapeutic Choice in Moderate to Severe HS
5



















